Absci’s (ABSI) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Absci (NASDAQ:ABSI) in a research report released on Wednesday morning,Benzinga reports. They currently have a $7.00 target price on the stock. HC Wainwright also issued estimates for Absci’s Q1 2025 earnings at ($0.27) EPS, Q2 2025 earnings at ($0.28) EPS, Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($0.83) EPS, FY2026 earnings at ($0.52) EPS, FY2027 earnings at ($0.31) EPS, FY2028 earnings at $0.20 EPS and FY2029 earnings at ($0.02) EPS.

Several other analysts also recently issued reports on ABSI. Guggenheim restated a “buy” rating and set a $10.00 price objective on shares of Absci in a report on Tuesday, December 3rd. Needham & Company LLC reiterated a “buy” rating and issued a $9.00 target price on shares of Absci in a report on Wednesday. Finally, KeyCorp dropped their target price on Absci from $6.00 to $5.00 and set an “overweight” rating on the stock in a report on Wednesday, January 8th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $8.57.

Absci Price Performance

NASDAQ ABSI opened at $3.01 on Wednesday. The stock’s 50-day moving average price is $3.86 and its two-hundred day moving average price is $3.66. The company has a current ratio of 5.63, a quick ratio of 5.63 and a debt-to-equity ratio of 0.01. The company has a market cap of $383.28 million, a PE ratio of -3.24 and a beta of 2.09. Absci has a 1 year low of $2.45 and a 1 year high of $6.72.

Absci (NASDAQ:ABSI) last posted its quarterly earnings data on Tuesday, March 18th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.03). The company had revenue of $0.67 million for the quarter, compared to analyst estimates of $1.77 million. Absci had a negative return on equity of 46.56% and a negative net margin of 2,321.56%. On average, analysts predict that Absci will post -0.89 EPS for the current year.

Hedge Funds Weigh In On Absci

Large investors have recently made changes to their positions in the business. PCA Investment Advisory Services Inc. acquired a new position in Absci in the fourth quarter worth approximately $26,000. Alpha Cubed Investments LLC acquired a new position in Absci in the fourth quarter worth approximately $26,000. Ballentine Partners LLC acquired a new position in Absci in the fourth quarter worth approximately $27,000. BNP Paribas Financial Markets acquired a new position in Absci in the fourth quarter worth approximately $28,000. Finally, Verdence Capital Advisors LLC acquired a new position in Absci in the fourth quarter worth approximately $37,000. Institutional investors and hedge funds own 52.05% of the company’s stock.

Absci Company Profile

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit.